Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Chiara Cremolini,Carlotta Antoniotti,Sara Lonardi,Daniele Rossini,Filippo Pietrantonio,Stefano Cordio,Francesca Bergamo,Federica Marmorino,Evaristo Maiello,Alessandro Passardi,Gianluca Masi,Emiliano Tamburini,Daniele Santini,Roberta Grande,Alberto Zaniboni,Cristina Granetto,Sabina Murgioni,Giuseppe Aprile,Luca Boni,Alfredo Falcone

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

2019

3508Background: In the phase III TRIBE study FOLFOXIRI/bev significantly improved Response Rate (RR), PFS and OS when compared with FOLFIRI/bev as initial treatment of mCRC. However, the actual adv...

Keywords:

Physical therapy
Oncology
Internal medicine
Medicine
FOLFOXIRI
initial treatment
FOLFIRI
randomized strategy
second line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations